I agree 1S and yes Paxalisib does continue to outperform anything else in the PI3K space - if the company did perform as well as the drug we would already be set... I hope JF will rise to the challenge - we will see!
Good to see so many studies to report in the next 4 months - even if some push longer we should still get at least a few come through.
should be an interesting spring/summer
